PSI-353661

PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes[1][3].

Product Specifications

CAS Number

[1231747-08-2]

Product Name Alternative

GS-558093

UNSPSC

12352005

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/psi-353661.html

Solubility

10 mM in DMSO

Smiles

COC1=NC(N)=NC2=C1N=CN2[C@@H]([C@@](F)(C)[C@@H]3O)O[C@@H]3CO[P@@](N[C@@H](C)C(OC(C)C)=O)(OC4=CC=CC=C4)=O

Molecular Formula

C24H32FN6O8P

Molecular Weight

582.52

References & Citations

[1]Wonsuk Chang, et al. Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. ACS Med Chem Lett. 2010 Dec 17;2 (2) :130-5. |[2]Furman PA, et al. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res. 2011 Aug;91 (2) :120-32. |[3]Yugo Kai, et al. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.